Department of Radiation Oncology, University Medical Center Groningen/University of Groningen, Groningen, The Netherlands.
Int J Radiat Oncol Biol Phys. 2011 Mar 15;79(4):1216-24. doi: 10.1016/j.ijrobp.2010.05.012. Epub 2010 Aug 21.
To test the hypothesis that scanned intensity-modulated proton therapy (IMPT) results in a significant dose reduction to the parotid and submandibular glands as compared with intensity-modulated radiotherapy with photons (IMRT) and three-dimensional conformal radiotherapy (3D-CRT) for oropharyngeal cancer. In addition, we investigated whether the achieved dose reductions would theoretically translate into a reduction of salivary dysfunction and xerostomia.
Ten patients with N0 oropharyngeal carcinoma were used. The intensity-modulated plans delivered simultaneously 70 Gy to the boost planning target volume (PTV2) and 54 Gy to the elective nodal areas (PTV1). The 3D-CRT technique delivered sequentially 70 Gy and 46 Gy to PTV2 and PTV1, respectively. Normal tissue complication probabilities were calculated for salivary dysfunction and xerostomia.
Planning target volume coverage results were similar for IMPT and IMRT. Intensity-modulated proton therapy clearly improved the conformity. The 3D-CRT results were inferior to these results. The mean dose to the parotid glands by 3D-CRT (50.8 Gy), IMRT (25.5 Gy), and IMPT (16.8 Gy) differed significantly. For the submandibular glands no significant differences between IMRT and IMPT were found. The dose reductions obtained with IMPT theoretically translated into a significant reduction in normal tissue complication probability.
Compared with IMRT and 3D-CRT, IMPT improved sparing of the organs at risk, while keeping similar target coverage results. The dose reductions obtained with IMPT vs. IMRT and 3D-CRT varied widely per individual patient. Intensity-modulated proton therapy theoretically translated into a clinical benefit for most cases, but this requires clinical validation.
检验以下假说,即与光子调强放疗(IMRT)和三维适形放疗(3D-CRT)相比,扫描调强质子治疗(IMPT)可显著降低口咽癌患者的腮腺和颌下腺剂量。此外,我们还研究了所实现的剂量降低是否会在理论上转化为唾液腺功能障碍和口干的减少。
纳入 10 例 N0 口咽癌患者。调强计划同时给予靶区 70Gy(PTV2)和 54Gy(PTV1)的剂量。3D-CRT 技术依次给予 PTV2 和 PTV1 70Gy 和 46Gy 的剂量。计算唾液腺功能障碍和口干的正常组织并发症概率。
IMPT 和 IMRT 的靶区覆盖结果相似。IMPT 明显改善了适形性,3D-CRT 结果则较差。腮腺的平均剂量分别为 3D-CRT(50.8Gy)、IMRT(25.5Gy)和 IMPT(16.8Gy),差异具有统计学意义。颌下腺的剂量在 IMRT 和 IMPT 之间无显著差异。与 IMRT 和 3D-CRT 相比,IMPT 获得的剂量降低理论上可显著降低正常组织并发症的概率。
与 IMRT 和 3D-CRT 相比,IMPT 改善了危及器官的保护,同时保持了相似的靶区覆盖结果。IMPT 相对于 IMRT 和 3D-CRT 的剂量降低因个体患者而异。IMPT 理论上可转化为大多数情况下的临床获益,但这需要临床验证。